Literature DB >> 29976737

Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.

Silvia Martinelli1, Rossana Maffei1, Stefania Fiorcari1, Chiara Quadrelli1, Patrizia Zucchini1, Stefania Benatti1, Leonardo Potenza1, Mario Luppi1, Roberto Marasca2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29976737      PMCID： PMC6269319          DOI： 10.3324/haematol.2017.187070

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 2.  Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Authors:  David S Sanford; William G Wierda; Jan A Burger; Michael J Keating; Susan M O'Brien
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-19

3.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

4.  Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

Authors:  Christian Grommes; Anas Younes
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

5.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.

Authors:  Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug
Journal:  Blood       Date:  2010-01-15       Impact factor: 22.113

6.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors:  Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

7.  The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells.

Authors:  Klaus Okkenhaug; Daniel T Patton; Antonio Bilancio; Fabien Garçon; Wendy C Rowan; Bart Vanhaesebroeck
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

Review 8.  Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.

Authors:  Klaus Okkenhaug; Khaled Ali; Bart Vanhaesebroeck
Journal:  Trends Immunol       Date:  2007-01-05       Impact factor: 16.687

Review 9.  Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Authors:  Iris de Weerdt; Suzanne M Koopmans; Arnon P Kater; Michel van Gelder
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

10.  Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia.

Authors:  Taeeun Kim; Se Yoon Park; Hyun-Jung Lee; Sun-Mi Kim; Heungsup Sung; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889
View more
  8 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma.

Authors:  Paul J Hengeveld; Eva de Jongh; Peter E Westerweel; Mark-David Levin
Journal:  BMJ Case Rep       Date:  2020-07-05

Review 3.  Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

Authors:  Ebru Aydin; Sebastian Faehling; Mariam Saleh; Laura Llaó Cid; Martina Seiffert; Philipp M Roessner
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

4.  Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks.

Authors:  Zuzana Mikulkova; Gayane Manukyan; Peter Turcsanyi; Milos Kudelka; Renata Urbanova; Jakub Savara; Eliska Ochodkova; Yvona Brychtova; Jan Molinsky; Martin Simkovic; David Starostka; Jan Novak; Ondrej Janca; Martin Dihel; Pavlina Ryznerova; Lekaa Mohammad; Tomas Papajik; Eva Kriegova
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

Review 5.  Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.

Authors:  Xuetong Chu; Yizhi Bu; Xiaoping Yang
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

Review 6.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

Review 7.  Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.

Authors:  Jessica S Little; Zoe F Weiss; Sarah P Hammond
Journal:  J Fungi (Basel)       Date:  2021-12-10

8.  The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.

Authors:  Christiane Braun; Sebastian Schlaweck; Solveig Nora Daecke; Peter Brossart; Annkristin Heine
Journal:  Cancer Immunol Immunother       Date:  2021-06-25       Impact factor: 6.968
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.